Setting up baseline labs before a peptide cycle

Baseline labs are the cheapest insurance policy in a peptide protocol. Without them, you cannot tell whether a side effect during the cycle is the peptide or a pre-existing condition; you cannot tell whether GH secretagogues actually pushed IGF-1; you cannot tell whether a marker that "looks elevated" was elevated before you started. A pre-cycle lab panel is one or two hours of effort for results that frame the rest of the cycle. This is what to order, why each marker matters, and how to use the results.

Why baseline labs matter

Three reasons that hold across every peptide:

1. Differential diagnosis if something goes wrong. If you develop fatigue at week 3, a baseline metabolic panel tells you whether your fasting glucose was already creeping up.
2. Effect measurement. GH secretagogue cycles are often evaluated by IGF-1 movement. Without a pre-cycle IGF-1, you have no idea whether the cycle worked.
3. Stop-criterion data. Some markers (IGF-1 above 300 ng/mL, hematocrit above 52%) define when to stop. Without baseline, you don't know whether you started near or far from those thresholds.

For the broader framework, see peptides and bloodwork and when to stop a cycle.

The minimum baseline panel

A useful baseline for any peptide cycle:

That's the floor. Most direct-to-consumer lab services offer this bundle as a standard package.

Peptide-specific additions

Some peptides warrant additional markers:

GH secretagogues (Sermorelin, Ipamorelin, CJC-1295, Tesamorelin, MK-677)

For more, see the GH secretagogues pillar.

IGF-1 LR3

For protocol-level guidance, see IGF-1 LR3 protocol.

MOTS-c

For more, see MOTS-c.

BPC-157, TB-500, GHK-Cu (recovery / cosmetic)

The minimum panel above is sufficient for most users. These peptides don't have well-established systemic markers that move predictably during a cycle, so the baseline is mostly for differential diagnosis if a side effect appears.

How to actually order labs

Three pathways exist:

1. Through your physician. If you have a clinician aware of the cycle, this is the cleanest route. Insurance coverage varies. Lead time depends on the clinic.

2. Direct-to-consumer lab services. Several US companies (and equivalents in other countries) offer comprehensive panels without a physician order. You order online, visit a draw site, results come back in days. Out-of-pocket cost is the price model; insurance does not apply.

3. Self-pay through a clinic lab. Some hospital systems and independent labs offer self-pay panels. Pricing varies widely.

The point is not which route — it's that all three exist, and one of them works for nearly everyone.

Timing the draw

A few timing rules:

• Fasting. Glucose, lipids, and insulin all need overnight fast (8–12 hours)
• AM cortisol. Draw before 9 a.m. for meaningful cortisol values
• IGF-1. Time of day matters less; consistency matters more — re-test at the same time of day
• Distance from peptide. Draw before the cycle starts. Re-tests during the cycle should be timed consistently relative to last injection

If you're already mid-cycle and didn't get baseline, drawing now still establishes a reference point — but it's a "current state," not a true baseline.

Reading the results — what's normal vs what to watch

A few key markers and their typical ranges:

These are population reference ranges. Your personal "normal" matters more — which is why baseline data is the point.

Re-testing during the cycle

For most cycles, two re-tests are useful:

For long cycles or higher-risk protocols, an early-cycle re-test (week 2) catches dramatic moves quickly. For low-risk recovery peptides, end-of-cycle alone is often sufficient.

A worked example: GH secretagogue baseline panel

Suppose you're starting a 12-week Ipamorelin + CJC-1295 (no DAC) cycle. The baseline order:

Total panel size: 8 tests. Time required: one draw, fasting, before 9 a.m. Cost: variable, typically a few hundred dollars at retail lab pricing.

Re-tests at week 6 and week 14 (two weeks post-cycle) — same panel, same time of day, same fasting protocol.

The output is a three-data-point picture of how IGF-1, glucose, and the other markers moved across the cycle. That picture is the entire point of the cycle's data set.

A worked example: BPC-157 minimum baseline

For a 6-week BPC-157 cycle for an Achilles issue:

Total: 5 tests. Re-test at end of cycle. The data set isn't dramatic — but if something unusual shows up, you have a comparison point.

Lab interpretation pitfalls

Three common mistakes when reading lab results:

1. Comparing to "ideal" rather than to your baseline. A TSH of 2.5 mIU/L is in the normal range. If it was 1.8 before the cycle, it moved — and the movement is the data, not the absolute number.

2. Single-marker panic. A single elevated ALT can be alcohol the night before, intense training, or measurement noise. Re-test before drawing conclusions.

3. Ignoring the trend. Three slightly-elevated fasting glucose readings across baseline, mid-cycle, end-of-cycle is more meaningful than one mildly-elevated value.

For more on stop criteria specifically, see when to stop a cycle.

When to involve a clinician

Some signals make the answer obvious:

• Hematocrit above 52% on a GH secretagogue cycle
• IGF-1 above 300 ng/mL on a GH secretagogue cycle
• Fasting glucose above 110 mg/dL or HbA1c above 5.9% during a cycle
• Liver enzymes more than 2x the upper reference
• Any marker outside reference range that wasn't outside at baseline
• New symptoms that pair with a moved marker

A clinician aware of the cycle can interpret results in context. A clinician unaware can usually still interpret the labs themselves; the cycle context is more about treatment than reading.

What baseline labs don't catch

Honest caveat: baseline panels are good at the well-studied markers. They won't catch:

• Subtle endocrine changes that aren't on a standard panel (free testosterone, SHBG, etc., need to be specifically ordered)
• Acute reactions that happen between draws
• Side effects that don't have a lab signature (mood changes, tendon stiffness, etc.)
• Vendor-quality issues (the peptide could be wrong; labs measure your physiology, not the vial)

Baselines are necessary, not sufficient. Pair them with subjective tracking and a stop-criterion list. For the protocol-level view, see building your first peptide protocol.

A summary table: minimum baseline by peptide

This is the simplest defensible setup. It doesn't include everything; it includes enough to detect the typical signals.

Related reading

• Peptides and bloodwork
• When to stop a cycle
• Building your first peptide protocol
• GH secretagogues guide
• Mistakes that derail first peptide cycles